Deaths / year
0
GBD (indicative unless refreshed)
DALYs / year
20,000
GBD
Pathogen
Bacteria
Post-infectious
Chronic disease
Persistent symptoms
n/a
Post-infectious syndrome & persistent symptoms
Whether a post-acute infection syndrome is documented and the literature proportion with persistent symptoms.
Post-acute status
Chronic destructive skin/bone/cartilage lesions if untreated
Classification
Chronic disease
Onset
chronic/late
Persistent-symptom %
not quantified as a single figure (see notes)
Source: WHO yaws eradication
Therapeutic agents by stage
Vector control, prevention, acute treatment, and post-infectious care. Only agents with published evidence are shown by default.
Prevention
| Agent | Type | Status | Mechanism / role | Source |
|---|---|---|---|---|
| Active case finding & contact treatment | Prevention | Approved | Interrupt transmission | WHO yaws eradication |
Acute phase
| Agent | Type | Status | Mechanism / role | Source |
|---|---|---|---|---|
| Azithromycin (single dose) | Antibiotic | Approved | WHO yaws eradication strategy | WHO EML / standard of care |
| Benzathine penicillin G | Antibiotic | Approved | Alternative single-dose injection | WHO EML / standard of care |
Post-infectious phase
| Agent | Type | Status | Mechanism / role | Source |
|---|---|---|---|---|
| Bone & cartilage lesion management | Supportive | Approved | Late destructive yaws (gangosa) | WHO |
Associated drug targets (Open Targets): CA4
Burden: IHME GBD (indicative seed unless refreshed) · Therapeutics: curated WHO EML / SOC + Open Targets pipeline · Post-infectious data: curated peer-reviewed literature · Ontology: MONDO_0006019 · Updated 2026-07-10. Associations, not a diagnostic test.